Panteli Theocharous, Garuda Therapeutics

As a senior-level industry executive in prior CMO roles and a cancer immunotherapy expert, Dr. Theocharous brings extensive experience in clinical development in malignant and benign haematological disorders, life cycle management, as well as regulatory and payer submissions. Specifically, Dr. Theocharous led development of first-generation clinical CAR-T, novel cell therapy applications in malignant diseases, and gene-directed therapies in benign disorders. Most recently, Dr. Theocharous served as Global Head, Cell and Gene Therapy Strategy Lead at PPD, part of Thermo Fisher Scientific. Prior to PPD, Dr. Theocharous held global Clinical and Medical Affairs leadership roles at Cell Therapeutics Inc. and Janssen Oncology, and was Director for Stem Cell Transplantation and Advanced Therapies at the Royal Free Hospital in London. In the clinical arena, Dr. Theocharous worked with Professor A. Victor Hoffbrand in hematologic disorders and under mentorship by Professor H. Grant Prentice in haematopoietic stem cell transplantation. Dr. Theocharous received an MS in applied clinical haematology, and cancer medicine related higher degrees from the Royal Free and University College Medical School at the University of London. Dr. Theocharous has a successful track record of significant executive-level client consultation and strategic advisement including leadership and influence at CEO and biotech board level.